{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=M-M-R-II&page=3", "query": { "intervention": "M-M-R-II", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 125, "total_pages": 13, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=M-M-R-II&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=M-M-R-II&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-20T17:16:27.868Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00197015", "title": "Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis A" ], "interventions": [ { "name": "Havrix®", "type": "BIOLOGICAL" }, { "name": "M-M-R®II", "type": "BIOLOGICAL" }, { "name": "VARIVAX®", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "12 Months", "maximum_age": "13 Months", "sex": "ALL", "summary": "12 Months to 13 Months" }, "enrollment_count": 1474, "start_date": "2003-10-06", "completion_date": "2009-06-09", "has_results": true, "last_update_posted_date": "2018-07-31", "last_synced_at": "2026-10-20T17:16:27.868Z", "location_count": 42, "location_summary": "Cabot, Arkansas • Jonesboro, Arkansas • North Little Rock, Arkansas + 37 more", "locations": [ { "city": "Cabot", "state": "Arkansas" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "North Little Rock", "state": "Arkansas" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Oakland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00197015" }, { "nct_id": "NCT00696696", "title": "Study of Gemcitabine and Erlotinib Plus Sorafenib (GES) in Metastatic Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Erlotinib", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2007-09", "completion_date": "2013-06", "has_results": true, "last_update_posted_date": "2016-06-30", "last_synced_at": "2026-10-20T17:16:27.868Z", "location_count": 3, "location_summary": "Palm Springs, California • New York, New York", "locations": [ { "city": "Palm Springs", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00696696" }, { "nct_id": "NCT04745949", "title": "PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma", "Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Lymphoma", "Ann Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Lymphoma", "Ann Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Lymphoma" ], "interventions": [ { "name": "Brentuximab Vedotin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2021-05-10", "completion_date": "2027-08-03", "has_results": false, "last_update_posted_date": "2026-02-19", "last_synced_at": "2026-10-20T17:16:27.868Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04745949" }, { "nct_id": "NCT01346293", "title": "Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Tetanus", "Diphtheria", "Pertussis", "Measles", "Polio" ], "interventions": [ { "name": "Diphtheria and Tetanus Toxoids and Acellular Pertussis + Measles, Mumps, Rubella + Varicella Virus", "type": "BIOLOGICAL" }, { "name": "Diphtheria and Tetanus Toxoids and Acellular Pertussis + Poliovirus + MMR + Varicella Virus", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sanofi Pasteur, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "4 Years", "maximum_age": "6 Years", "sex": "ALL", "summary": "4 Years to 6 Years" }, "enrollment_count": 3372, "start_date": "2011-04", "completion_date": "2013-09", "has_results": true, "last_update_posted_date": "2015-06-03", "last_synced_at": "2026-10-20T17:16:27.868Z", "location_count": 71, "location_summary": "Birmingham, Alabama • Pinson, Alabama • Trussville, Alabama + 60 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Pinson", "state": "Alabama" }, { "city": "Trussville", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT01346293" }, { "nct_id": "NCT00861744", "title": "Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rubella", "Mumps", "Measles", "Measles-Mumps-Rubella Vaccine" ], "interventions": [ { "name": "GSK Biological's investigational vaccine 209762", "type": "BIOLOGICAL" }, { "name": "M-M-R® II (Merck and Co)", "type": "BIOLOGICAL" }, { "name": "Varivax®", "type": "BIOLOGICAL" }, { "name": "Havrix®", "type": "BIOLOGICAL" }, { "name": "Prevnar®", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "12 Months", "maximum_age": "15 Months", "sex": "ALL", "summary": "12 Months to 15 Months" }, "enrollment_count": 1259, "start_date": "2009-06-03", "completion_date": "2012-06-18", "has_results": true, "last_update_posted_date": "2020-01-03", "last_synced_at": "2026-10-20T17:16:27.868Z", "location_count": 45, "location_summary": "Tuscaloosa, Alabama • Conway, Arkansas • Jonesboro, Arkansas + 42 more", "locations": [ { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Conway", "state": "Arkansas" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00861744" }, { "nct_id": "NCT01691898", "title": "A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Follicular Lymphoma", "Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "Pinatuzumab Vedotin", "type": "DRUG" }, { "name": "Polatuzumab Vedotin", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 231, "start_date": "2012-09-27", "completion_date": "2019-02-07", "has_results": true, "last_update_posted_date": "2020-02-21", "last_synced_at": "2026-10-20T17:16:27.868Z", "location_count": 26, "location_summary": "Los Angeles, California • Stanford, California • Denver, Colorado + 21 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Fort Myers", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01691898" }, { "nct_id": "NCT00013871", "title": "Pneumococcal Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Receiving Anti-HIV Drugs", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV Infections", "Hepatitis B", "Measles", "Pneumococcal Infections", "Pertussis" ], "interventions": [ { "name": "Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed", "type": "BIOLOGICAL" }, { "name": "Measles-Mumps-Rubella Vaccine (Live)", "type": "BIOLOGICAL" }, { "name": "Pneumococcal Vaccine, Polyvalent (23-valent)", "type": "BIOLOGICAL" }, { "name": "Pneumococcal Conjugate Vaccine, Heptavalent", "type": "BIOLOGICAL" }, { "name": "Hepatitis B Vaccine (Recombinant)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "2 Years to 18 Years" }, "enrollment_count": 300, "start_date": null, "completion_date": "2004-11", "has_results": false, "last_update_posted_date": "2021-11-01", "last_synced_at": "2026-10-20T17:16:27.868Z", "location_count": 38, "location_summary": "Birmingham, Alabama • Long Beach, California • Los Angeles, California + 26 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00013871" }, { "nct_id": "NCT03064867", "title": "Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Diffuse Large B-cell-lymphoma" ], "interventions": [ { "name": "Venetoclax", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Molly Gallogly", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "2017-06-26", "completion_date": "2023-08-12", "has_results": false, "last_update_posted_date": "2022-11-16", "last_synced_at": "2026-10-20T17:16:27.868Z", "location_count": 3, "location_summary": "St Louis, Missouri • Cleveland, Ohio", "locations": [ { "city": "St Louis", "state": "Missouri" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03064867" }, { "nct_id": "NCT00005792", "title": "Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma", "Plasma Cell Neoplasm" ], "interventions": [ { "name": "etoposide phosphate", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "topotecan", "type": "DRUG" }, { "name": "Autologous Stem Cell Rescue", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": "69 Years", "sex": "ALL", "summary": "15 Years to 69 Years" }, "enrollment_count": 131, "start_date": "1998-06-02", "completion_date": "2018-11-01", "has_results": false, "last_update_posted_date": "2019-11-08", "last_synced_at": "2026-10-20T17:16:27.868Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005792" }, { "nct_id": "NCT04333732", "title": "CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "COVID 19" ], "interventions": [ { "name": "MR or M-M-R II ® vaccine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3411, "start_date": "2020-09-04", "completion_date": "2021-12-03", "has_results": true, "last_update_posted_date": "2024-03-26", "last_synced_at": "2026-10-20T17:16:27.868Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04333732" } ] }